PIK3CA扩增与PTEN缺失对套细胞淋巴瘤生物学行为及靶向治疗敏感性的影响
本研究在5株套细胞淋巴瘤(MCL)细胞系中转入PIK3CA(PIK3CA UP)并对PTEN基因进行敲除/敲低(PTEN KO/KD),检测其对上游B细胞受体(BCR)信号依赖等表型的影响。PIK3CA过表达降低MCL对BCR促生存信号的依赖、降低氧化磷酸化水平并增加对糖酵解抑制剂2-脱氧葡萄糖的抵抗;PTEN KO表型更显著,出现AKT过度磷酸化与过度激活、对多种抑制剂(多数PI3K抑制剂、BTK抑制剂伊布替尼、BCL2抑制剂维奈克拉)抵抗增加、糖酵解速率增高且对2-脱氧葡萄糖抵抗、对BCR促生存信号依赖显著降低。结果提示PI3K通路异常可能重连相关信号,使MCL对BCR信号依赖降低、代谢与缺氧适应改善并出现靶向治疗抵抗。
要点
- PIK3CA过表达降低MCL对BCR促生存信号依赖并降低氧化磷酸化水平。
- PIK3CA过表达增加对2-脱氧葡萄糖抵抗,AKT磷酸化状态及PI3K抑制剂敏感性未变。
- PTEN KO致AKT过度激活、糖酵解增高,并对伊布替尼与维奈克拉等抵抗增加。
核心结论
- PI3K通路常见异常可能重连相关信号,使MCL对BCR信号依赖降低、代谢与缺氧适应改善并出现靶向治疗抵抗。
研究设计与样本
- 在5株MCL细胞系中转入PIK3CA(PIK3CA UP)并对PTEN基因进行敲除/敲低(PTEN KO/KD),检测相关表型,包括通过额外BCR敲除评估对上游BCR信号的依赖。
主要发现
- PIK3CA过表达降低所测MCL对BCR促生存信号的依赖,降低氧化磷酸化水平,并增加对糖酵解抑制剂2-脱氧葡萄糖的抵抗。
- PIK3CA过表达后AKT磷酸化状态不变,对一系列PI3K抑制剂的敏感性不变,提示PIK3CA扩增可能以AKT非依赖方式影响MCL细胞。
- PTEN KO表型更显著:AKT过度磷酸化与过度激活,对多种抑制剂(多数所测PI3K抑制剂、Bruton酪氨酸激酶抑制剂伊布替尼、BCL2抑制剂维奈克拉)抵抗增加。
- PTEN KO后糖酵解速率增高且对2-脱氧葡萄糖抵抗,对BCR促生存信号的依赖显著降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains and PTEN losses. To evaluate the biological and functional consequences of these aberrations in MCL, we have introduced transgenic expression of PIK3CA (PIK3CA UP) and performed knockout/knockdown of PTEN gene (PTEN KO/KD) in 5 MCL cell lines. The modified cell lines were tested for associated phenotypes including dependence on upstream B-cell receptor (BCR) signaling (by an additional BCR knockout). PIK3CA overexpression decreased the dependence of the tested MCL on prosurvival signaling from BCR, decreased levels of oxidative phosphorylation, and increased resistance to 2-deoxy-glucose, a glycolysis inhibitor. Unchanged protein kinase B (AKT) phosphorylation status and unchanged sensitivity to a battery of PI3K inhibitors suggested that PIK3CA gain might affect MCL cells in AKT-independent manner. PTEN KO was associated with a more distinct phenotype: AKT hyperphosphorylation and overactivation, increased resistance to multiple inhibitors (most of the tested PI3K inhibitors, Bruton tyrosine kinase inhibitor ibrutinib, and BCL2 inhibitor venetoclax), increased glycolytic rates with resistance to 2-deoxy-glucose, and significantly decreased dependence on prosurvival BCR signaling. Our results suggest that the frequent aberrations of the PI3K pathway may rewire associated signaling with lower dependence on BCR signaling, better metabolic and hypoxic adaptation, and targeted therapy resistance in MCL.
引用
- Bettazova N, Senavova J, Kupcova K, et al. Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024. PMID: 39158100. doi:10.1182/bloodadvances.2024013205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。